公众对血栓伴血小板减少综合征报告及监管措施后COVID-19腺病毒载体疫苗的看法——六个欧盟成员国的横断面研究
2022年6月至10月在丹麦、希腊、拉脱维亚、荷兰、葡萄牙和斯洛文尼亚开展多国横断面在线调查,共纳入3794名受访者,描述公众对血栓伴血小板减少综合征(TTS)的认知及其对接种COVID-19疫苗和其他疫苗意愿的影响,结果按国家描述性分析。
要点
- 六国中33.3%至68.3%的受访者报告熟悉TTS的症状和体征,但其中仅3.1%至61.4%能正确识别症状。
- 对Vaxzevria®和Jcovden®接种意愿变化最大在丹麦(61.2%),对其他COVID-19疫苗意愿变化最大在斯洛文尼亚(30.4%)。
- 未来COVID-19疫苗接种意愿下降最小在荷兰(20.9%),最大在拉脱维亚(69.1%)。
核心结论
- 公众对TTS的认知似乎影响了欧洲公众的看法,导致对Vaxzevria®和Jcovden®的接种意愿降低。
- 对其他COVID-19疫苗的接种意愿及广泛使用疫苗预防其他疾病的意愿也存在差异,似乎由国家卫生当局在应对和沟通COVID-19疫苗接种风险时采取的方式决定。
- 有必要进一步研究最佳风险沟通策略。
研究设计与样本
- 2022年6月至10月在丹麦、希腊、拉脱维亚、荷兰、葡萄牙和斯洛文尼亚开展的多国横断面在线调查。
- 最低目标受访者人数依据国家人口规模确定。
- 结果采用描述性分析。
主要发现
- 共纳入3794名受访者进行分析。
- 六国中33.3%至68.3%的受访者报告熟悉TTS的症状和体征,但其中3.1%至61.4%能正确识别症状。
- 对Vaxzevria®和Jcovden®接种意愿变化最大在丹麦(61.2%),对其他COVID-19疫苗意愿变化最大在斯洛文尼亚(30.4%)。
- 未来COVID-19疫苗接种意愿下降最小在荷兰(20.9%),最大在拉脱维亚(69.1%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In 2021, thrombosis with thrombocytopenia syndrome (TTS) was confirmed by the European Medicines Agency (EMA) as a rare side effect of the COVID-19 adenovirus vector vaccines Vaxzevria® and Jcovden®. This study aimed to describe the public's knowledge of TTS and how it affected the willingness to be vaccinated with COVID-19 vaccines and other vaccines in six European countries. METHODS: From June to October of 2022, a multi-country cross-sectional online survey was conducted in Denmark, Greece, Latvia, Netherlands, Portugal, and Slovenia. The minimum target of participants to be recruited was based on the size of the country's population. The results were analysed descriptively. RESULTS: In total, 3794 respondents were included in the analysis; across the six countries, 33.3 %-68.3 % reported being familiar with signs and symptoms of TTS, although 3.1-61.4 % of those were able to identify the symptoms correctly. The reported changes in willingness to be vaccinated against COVID-19 and with other vaccines varied per country. The largest reported change in the willingness to be vaccinated with Vaxzevria® and Jcovden® was observed in Denmark (61.2 %), while the willingness to be vaccinated with other COVID-19 vaccines changed most in Slovenia (30.4 %). The smallest decrease in willingness towards future vaccination against COVID-19 was reported in the Netherlands (20.9 %) contrasting with the largest decrease observed in Latvia (69.1 %). CONCLUSION: Knowledge about TTS seemed to have influenced the public's opinion in Europe resulting in less willingness to be vaccinated with Vaxzevria® and Jcovden®. Willingness for vaccination against COVID-19 with other vaccines and widespread use of vaccines to prevent other diseases also differed and seemed to be determined by the approaches taken by national health authorities when reacting to and communicating about COVID-19 vaccination risks. Further investigation of optimal risk communication strategies is warranted.
引用
- Buhl C, Jacobsen R, Almarsdóttir AB, et al. Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A cross-sectional study in six EU member states. Vaccine. 2024. PMID: 38182460. doi:10.1016/j.vaccine.2023.12.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。